Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Read More…
Industry, Sector and Symbol
Industry Computer programming, data processing, & other computer related
Sub-IndustryN/A
SectorBusiness Services
Phone888-798-5802
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$150.68 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Cardlytics (NASDAQ:CDLX) Frequently Asked Questions
What is Cardlytics' stock symbol?
Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."
How were Cardlytics' earnings last quarter?
Cardlytics Inc (NASDAQ:CDLX) issued its earnings results on Thursday, August, 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.23. The company had revenue of $48.73 million for the quarter, compared to analysts' expectations of $43.77 million. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 66.01%. Cardlytics's quarterly revenue was up 37.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.21) EPS. View Cardlytics' Earnings History.
When is Cardlytics' next earnings date?
What guidance has Cardlytics issued on next quarter's earnings?
Cardlytics updated its third quarter 2019 earnings guidance on Thursday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $46-50 million, compared to the consensus revenue estimate of $48.15 million.
What price target have analysts set for CDLX?
7 brokerages have issued 12 month price targets for Cardlytics' stock. Their predictions range from $26.00 to $43.00. On average, they expect Cardlytics' share price to reach $33.67 in the next twelve months. This suggests that the stock has a possible downside of 9.2%. View Analyst Price Targets for Cardlytics.
What is the consensus analysts' recommendation for Cardlytics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardlytics.
What are Wall Street analysts saying about Cardlytics stock?
Here are some recent quotes from research analysts about Cardlytics stock:
- 1. According to Zacks Investment Research, "Cardlytics, Inc. is engaged in developing a purchase intelligence platform. The purchase data includes debit, credit and bill pay data from online and in-store transactions. It helps the marketers identify, reach and influence likely buyers at scale, and measure the impact of marketing spends. The Company also operates an advertising channel, Cardlytics Direct. Cardlytics Direct delivers tailored marketing for marketers and financial institutions. Cardlytics, Inc. is based in ATLANTA, United States. " (10/15/2019)
- 2. SunTrust Banks, Inc. analysts commented, "We hosted Cardlytics’ CEO and Co-Founder, Scott Grimes, and COO and Co- Founder, Lynne Laube, at our 6th annual internet and digital media conference for a fireside chat." (5/21/2019)
Has Cardlytics been receiving favorable news coverage?
News headlines about CDLX stock have been trending somewhat positive on Wednesday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cardlytics earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Cardlytics.
Are investors shorting Cardlytics?
Cardlytics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,410,000 shares, an increase of 11.4% from the August 30th total of 3,060,000 shares. Based on an average daily volume of 453,800 shares, the short-interest ratio is presently 7.5 days. Currently, 16.8% of the shares of the company are sold short. View Cardlytics' Current Options Chain.
Who are some of Cardlytics' key competitors?
Some companies that are related to Cardlytics include Switch (SWCH), Medallia (MDLA), DouYu International (DOYU), Pluralsight (PS), SVMK (SVMK), Eventbrite (EB), Internet Initiative Japan (IIJIY), Health Catalyst (HCAT), Qutoutiao (QTT), 21Vianet Group (VNET), Model N (MODN), HealthStream (HSTM), The Rubicon Project (RUBI), Aurora Mobile (JG) and TrueCar (TRUE).
What other stocks do shareholders of Cardlytics own?
Who are Cardlytics' key executives?
Cardlytics' management team includes the folowing people:
- Mr. Scott D. Grimes, Co-Founder, CEO & Director (Age 56)
- Ms. Lynne Marie Laube, Co-Founder, COO & Director (Age 49)
- Mr. David Evans, CFO & Head of Corp. Devel.
- Mr. Sathish Gaddipati, Chief Technology Officer (Age 52)
- Mr. Kirk L. Somers, Chief Legal & People Officer (Age 54)
When did Cardlytics IPO?
(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.
Who are Cardlytics' major shareholders?
Cardlytics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include CIBC Private Wealth Group LLC (0.15%). Company insiders that own Cardlytics stock include Aimia Inc, Bryce Youngren, Clifford Sosin, David Thomas Evans, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman. View Institutional Ownership Trends for Cardlytics.
Which major investors are selling Cardlytics stock?
CDLX stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC. Company insiders that have sold Cardlytics company stock in the last year include Aimia Inc, Bryce Youngren, David Thomas Evans, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman. View Insider Buying and Selling for Cardlytics.
How do I buy shares of Cardlytics?
Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cardlytics' stock price today?
One share of CDLX stock can currently be purchased for approximately $37.06.
How big of a company is Cardlytics?
Cardlytics has a market capitalization of $846.08 million and generates $150.68 million in revenue each year. The company earns $-53,040,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. View Additional Information About Cardlytics.
What is Cardlytics' official website?
How can I contact Cardlytics?
Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]
MarketBeat Community Rating for Cardlytics (NASDAQ CDLX)
MarketBeat's community ratings are surveys of what our community members think about Cardlytics and other stocks. Vote "Outperform" if you believe CDLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
